Financial Performance - For the six months ended September 30, 2024, the company reported total revenue of HKD 41,688,000, an increase of 0.93% compared to HKD 41,305,000 for the same period in 2023[7] - The gross profit for the same period was HKD 20,393,000, reflecting a gross margin of approximately 48.9%[7] - The net profit attributable to equity shareholders for the six months was HKD 3,439,000, compared to a loss of HKD 87,000 in the previous year[7] - Basic and diluted earnings per share for the period were HKD 0.42, compared to HKD 0.00 in the same period last year[7] - The group reported a profit attributable to owners of HKD 3,439,000 for the six months ended September 30, 2024, up from HKD 2,846,000 in 2023, marking a growth of 20.8%[45] - The group’s profit increased by approximately HKD 600,000 from HKD 2,800,000 for the six months ended September 30, 2023, to HKD 3,400,000 for the same period in 2024, primarily due to government subsidies received[69] Revenue Breakdown - The group's revenue from medical consumables increased to HKD 30,014,000 in 2024 from HKD 26,497,000 in 2023, representing a growth of 18.9%[32] - Revenue from medical equipment decreased to HKD 9,677,000 in 2024 from HKD 12,811,000 in 2023, a decline of 24.5%[32] - Total revenue for the group was HKD 41,688,000 in 2024, compared to HKD 41,305,000 in 2023, reflecting a slight increase of 0.9%[32] Assets and Liabilities - Total assets as of September 30, 2024, were HKD 103,793,000, slightly down from HKD 104,195,000 as of March 31, 2024[9] - As of September 30, 2024, the company's total assets minus current liabilities amounted to HKD 107,144,000, an increase from HKD 103,276,000 as of March 31, 2024, representing a growth of 3.4%[11] - The company's non-current liabilities, including lease liabilities, increased to HKD 2,516,000 as of September 30, 2024, compared to no non-current lease liabilities reported as of March 31, 2024[11] - Trade receivables decreased from HKD 15,414,000 as of March 31, 2024, to HKD 13,232,000 as of September 30, 2024, representing a decline of approximately 14.2%[49] - The net trade receivables after impairment provisions were HKD 11,814,000 as of September 30, 2024, down from HKD 13,943,000 as of March 31, 2024, indicating a decrease of about 15.3%[49] Cash Flow - The net cash from operating activities for the six months ended September 30, 2024, was HKD 623,000, compared to a cash outflow of HKD 2,764,000 for the same period in 2023[16] - The cash and cash equivalents at the end of the reporting period were HKD 57,884,000, a decrease from HKD 61,085,000 at the beginning of the period, representing a decline of 5.5%[16] - The company experienced a net cash outflow of HKD 2,104,000 in cash and cash equivalents during the reporting period, compared to a larger outflow of HKD 8,278,000 in the previous year[16] Corporate Governance - The company has confirmed that all information provided in the report is accurate and complete, with no misleading or fraudulent elements[6] - The board of directors is committed to ensuring compliance with GEM listing rules and has undertaken reasonable inquiries to verify the report's contents[6] - The company has complied with the GEM Listing Rules regarding the "Trading Musts" standards, with no violations reported by directors or employees[92] - The audit committee, established on March 1, 2018, consists of two independent non-executive directors and one non-executive director, ensuring compliance with applicable accounting standards[97] - The company has maintained a governance structure that separates the roles of the chairman and CEO, although both roles are currently held by Ms. Huang[96] Shareholder Information - As of September 30, 2024, the company has a significant shareholder, B&A Success, holding 568,028,001 shares, representing 71.00% of the total equity[89] - Dr. Miao Yan Shun, spouse of Ms. Huang, is deemed to have the same equity interest as Ms. Huang, also holding 568,028,001 shares, equating to 71.00%[88] - Mr. Zhao Wen Wei holds 9,620,000 shares in the company, which accounts for 1.20% of the total equity[89] Employee and Operational Insights - The group employed 50 staff members as of September 30, 2024, with employee costs amounting to approximately HKD 10,300,000, an increase from HKD 9,400,000 for the same period in 2023[80] - Administrative and other operating expenses rose by approximately HKD 600,000 or 3.6%, from about HKD 16,200,000 for the six months ended September 30, 2023, to about HKD 16,800,000 for the same period in 2024[67] Future Outlook - The group remains optimistic about the healthcare industry due to the growing elderly population and increasing health awareness among Hong Kong citizens[63] - The group is seeking suitable investment opportunities to diversify its business and enhance returns for shareholders[63]
君百延集团(08372) - 2025 - 中期业绩